Dr. Sznol on Combining Nivolumab and Ipilimumab for the Treatment of Advanced Melanoma

Mario Sznol, MD
Published: Tuesday, Jun 10, 2014

Mario Sznol, MD, professor, Internal Medicine, Yale Cancer Center, discusses a phase I trial that examined the combination of nivolumab and ipilimumab for the treatment of advanced melanoma. The data presented at the 2014 ASCO Annual Meeting was an updated survival and clinical activity analysis in initially enrolled cohorts and activity by BRAF mutation status.

In this trial, ipilimumab was held at a fixed dose of 3 mg/kg while nivolumab was escalated from 0.3 mg/kg to 3 mg/kg. The drugs were given together every 3 weeks for a total of 4 doses.

Initial results, presented at the 2013 ASCO Annual Meeting, demonstrated an objective response rate of 40% and an 80% survival rate at 1 year. With another year of follow-up, researchers showed a 1-year survival of 85%, 2-year survival rate of 79%, and median survival of 40 months in the first 53 patients. In a phase I/Ib trial in melanoma, these results are “essentially unprecedented,” Sznol says.

Ten years ago, median survival for patients with melanoma was 6-12 months. Even in this age of targeted therapies, Sznol says, median survival is just 20-24 months.

SELECTED
LANGUAGE
Mario Sznol, MD, professor, Internal Medicine, Yale Cancer Center, discusses a phase I trial that examined the combination of nivolumab and ipilimumab for the treatment of advanced melanoma. The data presented at the 2014 ASCO Annual Meeting was an updated survival and clinical activity analysis in initially enrolled cohorts and activity by BRAF mutation status.

In this trial, ipilimumab was held at a fixed dose of 3 mg/kg while nivolumab was escalated from 0.3 mg/kg to 3 mg/kg. The drugs were given together every 3 weeks for a total of 4 doses.

Initial results, presented at the 2013 ASCO Annual Meeting, demonstrated an objective response rate of 40% and an 80% survival rate at 1 year. With another year of follow-up, researchers showed a 1-year survival of 85%, 2-year survival rate of 79%, and median survival of 40 months in the first 53 patients. In a phase I/Ib trial in melanoma, these results are “essentially unprecedented,” Sznol says.

Ten years ago, median survival for patients with melanoma was 6-12 months. Even in this age of targeted therapies, Sznol says, median survival is just 20-24 months.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x